Intelligence Feed event · Equity · 2026-09-11

    GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff

    Question

    GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff

    Direct answer

    GSK's Specialty Medicines business, which represents over 40% of total corporate revenues, delivered 14% year-over-year growth during the first half of 2026 on strong HIV, respiratory, and oncology demand. To mitigate revenue loss from dolutegravir patent expirations scheduled for 2028, GSK is advancing over 20 Phase III clinical trial starts in 2026 to restock its late-stage commercial pipeline.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-11
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff”, revision 1, evidence through 2026-09-11. https://marketontology.com/market-events/2026-09-11/gsk-specialty-medicines-grow-14-in-h1-2026-ahead-of-2028-hiv-patent-cliff-1573f5

    EQUITY
    GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff
    GSK's Specialty Medicines business, which represents over 40% of total corporate revenues, delivered 14% year-over-year growth during the first half of 2026 on strong HIV, respiratory, and oncology demand. To mitigate revenue loss from dolutegravir patent expirations scheduled for 2028, GSK is advancing over 20 Phase III clinical trial starts in 2026 to restock its late-stage commercial pipeline.
    GSKGILD
    Impact
    60
    SEP 11
    SIG
    86%
    GSKGILD
    GSK Specialty Medicines Grow 14% in H1 2026 Ahead of 2028 HIV Patent Cliff
    GSK's Specialty Medicines business, which represents over 40% of total corporate revenues, delivered 14% year-over-year growth during the first half of 2026 on strong HIV, respiratory, and oncology demand. To mitigate revenue loss from dolutegravir patent expirations scheduled for 2028, GSK is advancing over 20 Phase III clinical trial starts in 2026 to restock its late-stage commercial pipeline.
    → Specialty medicine volume growth cushions GSK cash flow, but impending 2028 dolutegravir patent expirations require successful Phase III pipeline conversion to maintain pharma valuation multiples.
    Impact
    GSK's Specialty Medicines business, which represents over 40% of total corporate revenues, delivered 14% year-over-year growth during the first half of 2026 on strong HIV, respiratory, and oncology demand. To mitigate revenue loss from dolutegravir patent expirations scheduled for 2028, GSK is advancing over 20 Phase III clinical trial starts in 2026 to restock its late-stage commercial pipeline.
    Affected
    GSKGILD
    Transmission
    Specialty medicine volume growth cushions GSK cash flow, but impending 2028 dolutegravir patent expirations require successful Phase III pipeline conversion to maintain pharma valuation multiples.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GSKspecialty sales growth offset by pipeline replacement risk against 2028 patent expirationMixed1-3mSpecialty Medicines grew 14% in H1 2026, over 20 Phase III trials planned
    GILDHIV therapeutic market share dynamics and competitive trial readoutsWatch1-3mHIV therapy market peer

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month